J.R. Larrubia

ORCID: 0000-0002-6383-848X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Liver Disease Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Systemic Lupus Erythematosus Research
  • Immunotherapy and Immune Responses
  • T-cell and B-cell Immunology
  • Animal Virus Infections Studies
  • Diabetes and associated disorders
  • Cancer Immunotherapy and Biomarkers
  • Immunodeficiency and Autoimmune Disorders
  • Chemokine receptors and signaling
  • Protein purification and stability
  • Pancreatitis Pathology and Treatment
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • Phagocytosis and Immune Regulation
  • Liver Diseases and Immunity
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Social Media in Health Education
  • Biological Research and Disease Studies
  • Respiratory viral infections research
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms

Hospital Universitario de Guadalajara
2014-2024

Universidad de Alcalá
2013-2024

Monash Medical Centre
2013

Monash University
2013

Vall d'Hebron Hospital Universitari
2013

California Liver Research Institute
2008-2009

Sanjay Gandhi Post Graduate Institute of Medical Sciences
2008

Ganesh Shankar Vidyarthi Memorial Medical College
2008

Liver Institute Northwest
2008

Hospital Universitario La Paz
2006

Hepatitis B virus (HBV) is a noncytopathic virus, and the recognition of infected hepatocytes by HBV-specific CD8 cells has been assumed to be central mechanism causing both liver damage control. To understand role cytotoxic T in pathogenesis HBV infection, we used functional assays that require cell expansion vitro human histocompatibility leukocyte antigen (HLA)-peptide tetramers allow direct ex vivo quantification circulating liver-infiltrating cells. Two groups patients with persistent...

10.1084/jem.191.8.1269 article EN The Journal of Experimental Medicine 2000-04-10

Summary. In persistent hepatitis C virus (HCV) infection, HCV‐specific cytotoxic T lymphocyte (CTL) reactivity is impaired and this affects HCV control. Interleukin‐7 receptor (CD127) expression on these cells could regulate CTL through Mcl‐1/Bim balance modulation. Bim a pro‐apoptotic molecule blocked by the action of Mcl‐1. cell CTLs were compared according to CD127 phenotype. Peripheral blood lymphocytes (PBL) from HLA‐A2 + patients obtained. visualized staining PBL with anti‐CD8...

10.1111/j.1365-2893.2012.01618.x article EN Journal of Viral Hepatitis 2012-05-03

Summary Background Hepatitis B virus (HBV)‐specific CD8 + cell response restoration during nucleos(t)ide analogue (NUC) treatment could lead to off‐treatment HBV control in e‐antigen‐negative chronic hepatitis (CHBe(−)). Aim To predict this with variables involved T‐cell exhaustion for use as a stopping tool. Methods In NUC‐treated CHBe(−) patients, we considered functional cases HBV‐specific cells against core and polymerase epitopes able proliferate secrete type I cytokines after antigen...

10.1111/apt.16850 article EN Alimentary Pharmacology & Therapeutics 2022-02-27

Hepatitis C virus (HCV)-specific CD8+ T cells suffer a progressive exhaustion during persistent infection (PI) with HCV. This process could involve the positive immune checkpoint 4-1BB/4-1BBL through loss of its signal transducer, TRAF1. To address this issue, peripheral HCV-specific (pentamer-positive [pentamer+]/CD8+ cells) from patients PI and resolved (RI) after treatment were studied. The duration HCV liver fibrosis progression rate inversely correlated likelihood detection...

10.1128/jvi.01443-17 article EN Journal of Virology 2017-11-01

The addition of protease inhibitors (PIs) changed the hepatitis C virus (HCV) treatment standards and improved sustained viral response (SVR) rates in patients with genotype 1 HCV infection.Prospective, multicentre, national registry that includes naïve treatment-experienced infection, who had bridging fibrosis or cirrhosis were treated triple therapy (peginterferon alfa-2a alfa-2b, ribavirin boceprevir) as compassionate use, accordance Summary Product Characteristics.Most (68.2%) male, a...

10.1111/liv.12656 article EN Liver International 2014-08-11

Purpose: To explore visual outcomes in patients with extreme myopia receiving an implantable collamer lens (ICL) at −18.00 diopters (D), central port, followed by bioptics laser vision correction (laser situ keratomileusis [LASIK] or photorefractive keratectomy [PRK]) to address residual myopic astigmatism. Setting: Clínica Baviera (Aier Eye Hospital Group), Bilbao, Spain. Design: Retrospective analysis of cases. Methods: The study assessed uncorrected distance acuity, corrected acuity...

10.1097/j.jcrs.0000000000001438 article EN Journal of Cataract & Refractive Surgery 2024-03-06

BACKGROUNDAntiviral treatment of patients with chronic hepatitis B (CHB) in the grey zone comands risk management order to optimize health outcome.In this sense, identification HBV mutants related an increased hepatocellular carcinoma (HCC) could be useful identify subpopulations potential indication antiviral treatment. AIMTo analyze prevalence/persistence virus (HBV) preS and basal core promoter (BCP)/precore/core variants associated HCC development CHB zone. METHODS

10.3748/wjg.v25.i38.5883 article EN cc-by-nc World Journal of Gastroenterology 2019-10-14

HBe-antigen(Ag)-negative chronic hepatitis B virus (HBV) infection is characterized by little liver fibrosis progression and vigorous HBV-multispecific CD8+ T-cell response. To assess whether HBsAg level could discriminate different HBeAg-negative HBV subtypes with dissimilar quality of HBV-specific We recruited 63 patients in which indirect markers inflammation/fibrosis, portal pressure, viral load (VL), cell effector function were correlated level. A positive linear trend between APRI,...

10.3389/fimmu.2024.1352929 article EN cc-by Frontiers in Immunology 2024-03-13

Abstract Context.—Mast cells (MCs) have been implicated in fibrogenesis, angiogenesis, and immunity against bacteria. These 3 mechanisms participate the peritoneal pathology secondary to dialysis (PD) treatment. Despite their potential relevance PD-related pathology, few studies focused on MCs. Objective.—To evaluate possible variations number of MCs during PD Design.—A quantitative study tissue normal pathologic peritoneum. Parietal biopsies were collected from 4 groups: (1) controls (n =...

10.5858/2006-130-1188-mcqinp article EN Archives of Pathology & Laboratory Medicine 2006-08-01

ABSTRACT A mixture of deoxycorticosterone-1,2- 3 H (21-hydroxy-4-pregnene-3,20-dione) and corticosterone-4- 14 C (11β,21-dihydroxy-4-pregnene-3,20-dione) was injected in two cases at laparotomy into the intact foeto-placental circulation 15 minutes prior to interruption gestation. Metabolites present placenta various foetal tissues were separated isolated a radiochemically homogeneous form. In experiments, 58 86 per cent, respectively, administered radioactive material recovered from plus...

10.1530/acta.0.0640385 article EN European Journal of Endocrinology 1970-07-01

Summary In many countries, first‐generation protease inhibitors ( PI s)/peginterferon/ribavirin P / R ) still represent the only treatment option for HCV ‐infected patients. Subjects with advanced disease and previous failure to urgently need therapy, but they are under‐represented in clinical trials. All treatment‐experienced F 3/4 Metavir patients who received boceprevir BOC )+ I talian– S panish N ame atient rogram have been included this study. Multivariate logistic regression analysis...

10.1111/jvh.12342 article EN Journal of Viral Hepatitis 2014-10-14
Coming Soon ...